Roflumilast: In chronic obstructive pulmonary disease

Drugs

Volumn 70, Issue 12, 2010, Pages 1615-1627

  Sanford, Mark ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Chronic obstructive pulmonary disease; Research and development; Roflumilast, general

Indexed keywords

CIMETIDINE; ENOXACIN; ERYTHROMYCIN; FLUVOXAMINE; KETOCONAZOLE; ROFLUMILAST; SALMETEROL; TIOTROPIUM BROMIDE;

ABDOMINAL PAIN; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DIARRHEA; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; MAINTENANCE THERAPY; NAUSEA; PHARMACODYNAMICS; REVIEW; SIDE EFFECT; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; AMINOPYRIDINES; BENZAMIDES; BRONCHODILATOR AGENTS; CYCLOPROPANES; HUMANS; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 77955498534     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11205930-000000000-00000     Document Type: Review

References (30)

1. Yao H, de Boer W, Rahman I. Targeting lung inflammation: novel therapies for the treatment of COPD. Curr Respir Med Rev 2008; 4 (1): 57-68
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). At-a-glance outpatient reference guide for chronic obstructive pulmonary disease (COPD) [online]. Available from URL
3. Wedzicha JA, Seemungal TA. COPD exacerbations: defin-ing their cause and prevention. Lancet 2007 Sep 1; 370 (9589): 786-796
4. Hansel TT, Barnes JJ. New drugs for exacerbations of chro-nic obstructive pulmonary disease. Lancet 2009 Aug 29; 374 (9691): 744-755
5. Burgel P-R, Nesme-Meyer P, Chanez P, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009 Apr; 135 (4): 975-982
6. Barnes PJ, Celli BR. Systemic manifestations and comorbi-dities of COPD. Eur Respir J 2009; 33 (5): 1165-1185
7. Halpin D. Mortality in COPD: inevitable or preventable? Insights from the cardiovascular arena. COPD 2008 Jun; 5 (3): 187-200
8. O'Donnell DE. Assessment of bronchodilator efficacy in symptomatic COPD: is spirometry useful? Chest 2000 Feb; 117 (2 Suppl.): 42s-7s
9. Celli BR, MacNee W. Standards for the diagnosis and treat-ment of patients with COPD: a summary of the ATS/ERS position paper. ATS/ERS Task Force. Eur Respir J 2004; 23: 932-946
10. Hatzelmann A, Schudt C. Anti-inflammatory and immuno-modulatory potential of the novel PDE4 inhibitor ro-flumilast in vitro. J Pharmacol Exp Ther 2001; 297 (1): 267-279
11. European Medicines Agency. Daxas 500 micograms film-coated tablets: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/001179/WC500095209.pdf [Accessed 2010 Aug 2]
12. Nycomed. Nycomed and Forest Laboratories receive com-plete FDA response letter for roflumilast-no additional patient trials were requested [media release]. 2010 May 17 [online]. Available from URL, http://www.nycomed.com/News/ NewsReleases/2010/Nycomed%20and%20Forest% 20Laboratories%20receive%20complete%20FDA%20res ponse%20letter%20for%20Roflumilast.aspx
13. Hatzelmann A, Morcillo EJ, Lungarella G, et al. The preclinical pharmacology of roflumilast: a selective, oral phosphodies-terase inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2010 Aug; 23 (4): 235-256
14. Wohlsen A, Hirrle A, Tenor H, et al. Effect of cyclic AMP-elevating agents on airway ciliary beat frequency in central and lateral airways in rat precision-cut lung slices. Eur J Pharmacol 2010 Jun 10; 635 (1-3): 177-183
15. Martorana PA, Beume R, Lucattelli M, et al. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Resp Crit Care Med 2005 Oct; 172 (7): 848-853
16. Hohlfeld JM, Schoenfeld K, Lavae-Mokhtari M, et al. Ro-flumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial. Pulm Pharmacol Ther 2008 Aug; 21 (4): 616-623
17. Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduc-tion in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007 Dec; 62 (12): 1081-1087
18. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009 Aug 29; 374 (9691): 685-694
19. Bethke TD, Bohmer GM, Hermann R, et al. Dose-proportional intraindividual single-and repeated-dose pharmacokine-tics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin Pharmacol 2007 Jan; 47 (1): 26-36
20. Hauns B, Hermann R, Hunnemeyer A, et al. Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects. J Clin Pharmacol 2006 Oct; 46 (10): 1146-1153 (Pubitemid 44387414)
21. Lahu G, Hunnemeyer A, Diletti E, et al. Population phar-macokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model. Clin Pharmacokinet 2010; 49 (9): 589-606
22. Rabe KF, Bateman ED, O'Donnell D, et al. Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005 Aug 13-2005; 366 (9485): 563-571
23. Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007 Jul 15; 176 (2): 154-161
24. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Ro-flumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009 Aug 29; 374 (9691): 695-703
25. Jones PW, Quirk FH, Baveystock CM. The St Georges Res-piratory Questionnnaire. Respir Med 1991 Sep; 85 Suppl. B: 25-31
26. Mahler DA, Weinberg DH, Wells CK, et al. The measure-ment of dyspnea: contents, interobserver agreement, and physiologic correlates of two clinical indices. Chest 1984 Jun; 85 (6): 751-758
27. Eakin EG, Resnikoff PM, Prewitt LM, et al. Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. Chest 1998 Mar; 113 (3): 619-624
28. Rutten-van Molken MP, van Nooten FE, Lindemann M, et al. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease. Pharmacoeconomics 2007; 25 (8): 695-711
29. Martinez FJ, Rabe KF, Wouters EFM, et al. Time course and reversibility of weight decrease with roflumilast, a phosphodiesterase 4 inhibitor [abstract no. A4441]. 2010 American Thoracic Society (ATS) International Conference; 2010 May 14-19; New Orleans (LA)
30. Wouters EFM, Teichmann P, Brose M, et al. Effects of ro-flumilast, a phosphodiesterase 4 inhibitor, on body composition in chronic obstructive pulmonary disease [abstract no. A4473]. 2010 American Thoracic Society (ATS) International Conference; 2010 May 14-19; New Orleans (LA)